DrugPatentWatch Database Preview
Litigation Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
» See Plans and Pricing
Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Docket | Start Trial | Date Filed | 2020-06-12 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | DR. REDDY'S LABORATORIES, INC. | ||
| Patents | 10,583,110; 8,013,002; 8,927,592 | ||
| Attorneys | Kelly E. Farnan | ||
| Firms | Phillips, Goldman, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Apotex Corp.
The small molecule drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-09 | 107 | Claim Construction Chart | Chart for U.S. Patent Nos. 10,583,110 (“the ’110 patent”) and 10,716,777 (“the ’777 patent”). The…the ’110 patent. Exhibit B to the Joint Claim Construction Chart is a copy of the ’777 patent. Exhibit… ’110 Patent, Figs. 1-5 ’777 patent, Exhibit B, including…110 Patent at 2:43-3:41 Prosecution file history of the ’110 patent, … Prosecution file history of the ’777 patent, ’110 Patent at 8:61-65 Exhibit D | External link to document |
| 2020-12-01 | 178 | 13. The term “the ’110 patent” means United States Patent No. 10,583,110. …the ’777 patent” means United States Patent No. 10,716,777. 15. The term “patents-in-suit…States patent or patent application that directly or indirectly claims priority to the Patents-in-Suit…interest or right to the patents-in-suit and any product embodying any claim of the patents-in- suit. RESPONSE… any of the patents-in-suit, the infringement, validity or enforceability of those patents, or any | External link to document | |
| 2021-01-04 | 209 | Opinion - Memorandum Opinion | U.S. Patent No. 10,583,110 (“the ‘110 Patent”) and U.S. Patent No. 10,716,777 (“the ‘777 Patent”). The…OPINION providing claim construction for U.S. Patent Nos. 10,583,110 and 10,716,777. Within five days the parties… defined in the ‘110 and ‘777 Patents. ‘110 Patent 11:20-22; ‘777 Patent 11:19-20. This understanding …administration of said cabazitaxel.” ‘110 Patent 18:8-18. Claim 1 of the ‘777 Patent discloses a method using a “dose…cabazitaxel.” ‘777 Patent 18: 54- 61. 1 1 Why the ‘777 Patent, which is a continuation | External link to document |
| 2021-01-10 | 215 | Order | following te1ms in U.S. Patent Nos. 10,583,110 ("the '110 patent") and 10,716,777 ("…;777 patent") are constmed as set f01ih below: Term Patent Claims…resistant metastatic prostate cancer '110 patent: claim 1 castration resistant metastatic …after or after treatment with '777 patent: claim 1 treatment with docetaxel 1 docetaxel…the a method of increasing '110 patent: claim 1 intentional pmpose of increasing | External link to document |
| 2020-06-12 | 4 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,583,110 B2. (myr) (Entered… 12 June 2020 1:20-cv-00804 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
